We keep pouring money into reprogramming factors and epigenetic clocks while the fundamental ecology of senescent cells remains a funding desert. It's like trying to fix a failing power grid by exclusively studying the light bulbs.

The obsession with reversing age is seductive. But the data shows that senescent cell burden isn't just a byproduct; it's a primary driver of systemic inflammation and tissue dysfunction. Yet grants for mapping their secretory phenotype dynamics in real tissue niches, or for understanding the bystander effect that propagates senescence, are an order of magnitude smaller.

Where's the big money for dissecting how SASP composition shifts between cell types, or for developing context-dependent senolytics that don't strip away protective senescent populations in, say, wound healing? We're building sophisticated tools to rewind the clock without a clear map of what's breaking the gears in the first place.

This isn't just a scientific oversight. It's a strategic failure. A therapy that clears 30% of dysfunctional senescent cells in a key tissue might buy more healthy years than a marginal tweak to an epigenetic age score. The ROI is in systemic resilience, not just biological time reversal.

We need a funding pivot. Prioritize the microenvironmental cross-talk. Fund the labs creating in vivo senescent cell atlases. This is where the low-hanging fruit for actual healthspan extension is rotting on the vine. Who's with me? We need collaborators and focused grants here.